Cathie Wood Sells $5.2 Million in AI Stock; Discover What Ark Invest Acquired in Its Place
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Source: Benzinga
Ark Invest's Sale of Tempus AI Shares: Ark Invest, led by Cathie Wood, sold 62,352 shares of Tempus AI Inc for approximately $5.2 million, despite the company recently receiving FDA clearance for its RNA-based diagnostic device.
Recent Trading Activity: The firm has been reducing its position in Tempus AI over the past few weeks, having sold shares worth $3.76 million and $2.1 million in earlier transactions, while also making other trades in companies like Arcturus Therapeutics and Roku.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 60.270
Low
76.00
Averages
84.38
High
105.00
Current: 60.270
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $62.945 and a high of $92.65, with the last trade at $82.55, indicating significant volatility and shifts in investor sentiment within the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, as these liquidity shifts can significantly affect the performance of the underlying stocks held within the ETFs.
See More
Tempus AI Shareholder Sell-off Raises Market Concerns
- Shareholder Sell-off Impact: Gray Media and Blue Media, linked to CEO Eric Lefkofsky, sold a combined 166,250 shares of Tempus AI Class A stock on Monday for approximately $9.6 million, with average prices between $55.38 and $59.23, raising concerns about potential negative market sentiment.
- Market Reaction: Despite a 6% rise in Tempus AI's stock on Wednesday, reaching its highest level in over five months, the stock slipped 0.4% late Monday following the sell-off announcement, indicating investor apprehension regarding the company's future, especially amid intensifying competition in the healthcare AI sector.
- Healthcare AI Outlook: A research firm noted that Tempus may be closer to the “AI as physician” thesis than any other publicly traded healthcare tech company, although the theme remains in its early stages and valuations are deemed “about right,” suggesting investors should proceed with caution.
- Research Collaboration Progress: Tempus's partnership with Angiosarcoma Awareness aims to leverage its dataset of 600 de-identified patient records to study a rare cancer diagnosed in about 1,000 individuals annually in the U.S., demonstrating the company's ongoing commitment and potential in the precision medicine space.
See More
SoundThinking and SELLAS Options Trading Activity
- SoundThinking Options Activity: SoundThinking Inc (Symbol: SSTI) has seen an options trading volume of 800 contracts today, representing approximately 80,000 shares, which accounts for 62.1% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within SSTI, the $7.50 strike put option has been particularly active, with 799 contracts traded today, representing about 79,900 shares, reflecting investor expectations regarding potential downside risks for the stock.
- SELLAS Options Activity: SELLAS Life Sciences Group Inc (Symbol: SLS) has recorded an options trading volume of 50,636 contracts today, equating to approximately 5.1 million shares, or 61.3% of its average daily trading volume over the past month, showcasing strong market interest in its stock.
- High Volume Call Options: For SLS, the $15 strike call option has seen a trading volume of 3,278 contracts today, representing around 327,800 shares, indicating investor confidence in the stock's potential for future gains.
See More
Tempus AI Partners with Angiosarcoma Awareness to Advance Research
- Research Collaboration Initiated: Tempus AI has partnered with Angiosarcoma Awareness, Inc. to leverage approximately 600 de-identified angiosarcoma records, aiming to accelerate research on this rare cancer, which is expected to significantly enhance understanding of angiosarcoma biology and advance precision medicine.
- Data Resource Integration: This collaboration will integrate Tempus' multimodal molecular and clinical data to help researchers identify biological patterns and potential therapeutic opportunities, thereby overcoming challenges in rare cancer research related to data fragmentation and lack of effective pre-clinical models.
- Enhanced Patient Engagement: The collaboration builds on the Angiosarcoma Project launched in 2017, aiming to directly involve patients and families in angiosarcoma research, enhancing patient voices and participation in scientific discovery.
- Commitment to Precision Medicine: Tempus' Chief Medical Officer, Ezra Cohen, emphasized that precision medicine should not be limited by data availability, and this collaboration will provide better treatment options for rare cancer patients, reflecting the company's strong commitment to advancing precision medicine.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
Tempus AI Receives FDA Clearance for Atrial Fibrillation Prediction Software
- FDA Approval: Tempus AI's ECG software received FDA clearance in 2024 for predicting the risk of atrial fibrillation (AF) in patients aged 65 and older, marking a significant advancement in the field of precision medicine.
- Multi-Center Validation Study: The study evaluated 4,017 patients across three distinct clinical sites, demonstrating that the ECG-AI risk score exceeded pre-specified performance thresholds, indicating the technology's reliability in diverse clinical environments and potentially transforming early risk detection in cardiac care.
- Clinical Application Potential: Findings suggest that the Tempus ECG-AF software can assist clinicians in identifying hidden AF risks earlier, thereby helping to minimize serious complications such as stroke and heart failure, ultimately enhancing overall patient care quality.
- Technological Innovation: The Tempus ECG-AF is the first FDA-cleared ECG-AI device designed to analyze 12-lead ECG recordings to detect early signs of AF, further advancing the company's technological development in the cardiovascular disease sector.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $62.945 and a high of $92.65, with the last trade at $82.55, indicating significant volatility and shifts in investor sentiment within the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, as these liquidity shifts can significantly affect the performance of the underlying stocks held within the ETFs.
See More
Tempus AI Shareholder Sell-off Raises Market Concerns
- Shareholder Sell-off Impact: Gray Media and Blue Media, linked to CEO Eric Lefkofsky, sold a combined 166,250 shares of Tempus AI Class A stock on Monday for approximately $9.6 million, with average prices between $55.38 and $59.23, raising concerns about potential negative market sentiment.
- Market Reaction: Despite a 6% rise in Tempus AI's stock on Wednesday, reaching its highest level in over five months, the stock slipped 0.4% late Monday following the sell-off announcement, indicating investor apprehension regarding the company's future, especially amid intensifying competition in the healthcare AI sector.
- Healthcare AI Outlook: A research firm noted that Tempus may be closer to the “AI as physician” thesis than any other publicly traded healthcare tech company, although the theme remains in its early stages and valuations are deemed “about right,” suggesting investors should proceed with caution.
- Research Collaboration Progress: Tempus's partnership with Angiosarcoma Awareness aims to leverage its dataset of 600 de-identified patient records to study a rare cancer diagnosed in about 1,000 individuals annually in the U.S., demonstrating the company's ongoing commitment and potential in the precision medicine space.
See More
SoundThinking and SELLAS Options Trading Activity
- SoundThinking Options Activity: SoundThinking Inc (Symbol: SSTI) has seen an options trading volume of 800 contracts today, representing approximately 80,000 shares, which accounts for 62.1% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within SSTI, the $7.50 strike put option has been particularly active, with 799 contracts traded today, representing about 79,900 shares, reflecting investor expectations regarding potential downside risks for the stock.
- SELLAS Options Activity: SELLAS Life Sciences Group Inc (Symbol: SLS) has recorded an options trading volume of 50,636 contracts today, equating to approximately 5.1 million shares, or 61.3% of its average daily trading volume over the past month, showcasing strong market interest in its stock.
- High Volume Call Options: For SLS, the $15 strike call option has seen a trading volume of 3,278 contracts today, representing around 327,800 shares, indicating investor confidence in the stock's potential for future gains.
See More
Tempus AI Partners with Angiosarcoma Awareness to Advance Research
- Research Collaboration Initiated: Tempus AI has partnered with Angiosarcoma Awareness, Inc. to leverage approximately 600 de-identified angiosarcoma records, aiming to accelerate research on this rare cancer, which is expected to significantly enhance understanding of angiosarcoma biology and advance precision medicine.
- Data Resource Integration: This collaboration will integrate Tempus' multimodal molecular and clinical data to help researchers identify biological patterns and potential therapeutic opportunities, thereby overcoming challenges in rare cancer research related to data fragmentation and lack of effective pre-clinical models.
- Enhanced Patient Engagement: The collaboration builds on the Angiosarcoma Project launched in 2017, aiming to directly involve patients and families in angiosarcoma research, enhancing patient voices and participation in scientific discovery.
- Commitment to Precision Medicine: Tempus' Chief Medical Officer, Ezra Cohen, emphasized that precision medicine should not be limited by data availability, and this collaboration will provide better treatment options for rare cancer patients, reflecting the company's strong commitment to advancing precision medicine.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
Tempus AI Receives FDA Clearance for Atrial Fibrillation Prediction Software
- FDA Approval: Tempus AI's ECG software received FDA clearance in 2024 for predicting the risk of atrial fibrillation (AF) in patients aged 65 and older, marking a significant advancement in the field of precision medicine.
- Multi-Center Validation Study: The study evaluated 4,017 patients across three distinct clinical sites, demonstrating that the ECG-AI risk score exceeded pre-specified performance thresholds, indicating the technology's reliability in diverse clinical environments and potentially transforming early risk detection in cardiac care.
- Clinical Application Potential: Findings suggest that the Tempus ECG-AF software can assist clinicians in identifying hidden AF risks earlier, thereby helping to minimize serious complications such as stroke and heart failure, ultimately enhancing overall patient care quality.
- Technological Innovation: The Tempus ECG-AF is the first FDA-cleared ECG-AI device designed to analyze 12-lead ECG recordings to detect early signs of AF, further advancing the company's technological development in the cardiovascular disease sector.
See More
